Business

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Guggenheim Second Annual Healthcare Innovation Conference, Stifel 2025 Healthcare Conference, and Jefferies 2025 London Healthcare Conference. With an initial focus in oncology, Foghorn’s Gene Traffic Contr

articleFoghorn Therapeutics Inc.November 3, 20252/company/foghorn-therapeutics-inc/news/foghorn-therapeutics-participate-three-upcoming-123000795
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

About this update from Foghorn Therapeutics Inc.

[{"type":"image","alt":"Foghorn Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Foghorn Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":75,"url":"https://media.zenfs.com/en/globenewswire.com/c48e0461026ebce223e5a31638f2e086"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ql7RNPJuQ1jhwreokk4ggw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c48e0461026ebce223e5a31638f2e086","width":300,"height":75}},"lazy":false},{"type":"text","content":"CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Guggenheim Second Annual Healthcare Innovation Conference, Stifel 2025 Healthcare Conference, and Jefferies 2025 London Healthcare Conference. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.","length":642,"tagName":"p"},{"type":"text","content":"Guggenheim Second Annual Healthcare Innovation Conference","length":57,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Fireside Chat: Monday, November 10, 2025, at 11:00 a.m. ET","length":58,"tagName":"p"}]},{"val":[{"type":"text","content":"Presenter: Adrian Gottschalk, President and Chief Executive Officer","length":67,"tagName":"p"}]},{"val":[{"type":"text","content":"Management will also participate in one-on-one meetings","length":55,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":180,"olType":false},{"type":"text","content":"Stifel 2025 Healthcare Conference","length":33,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Presentation: Thursday, November 13, 2025, at 4:00 p.m. ET","length":58,"tagName":"p"}]},{"val":[{"type":"text","content":"Presenter: Adrian Gottschalk, President and Chief Executive Officer","length":67,"tagName":"p"}]},{"val":[{"type":"text","content":"Management will also participate in one-on-one meetings","length":55,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":180,"olType":false},{"type":"text","content":"Je...

More updates from Foghorn Therapeutics Inc.

Healthcare ConferenceLondon Healthcare ConferenceFoghorn TherapeuticsChief Executive OfficerAdrian GottschalkFireside Chat